DigestRedComo funciona
Red
/
Empresas
Ar
No verificado

Aro Biotherapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
24/09/2025
Industria
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)
Fuente
Aro Biotherapeutics
Editor
Business Wire
1.00
0
11/02/2025
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
Mercado laboral
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
Fuente
Aro Biotherapeutics
Editor
Business Wire
1.00
0
05/02/2025
Higiene alimentaria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Industria
Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD)
Fuente
Aro Biotherapeutics
Editor
Business Wire
1.00
0
23/01/2025
Industria
Higiene alimentaria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)
Fuente
Aro Biotherapeutics
Editor
Business Wire
1.00
0
07/01/2025
Mercado laboral
Higiene alimentaria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer
Fuente
Aro Biotherapeutics
Editor
Business Wire
1.00
0
29/10/2024
Industria
Higiene alimentaria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)
Fuente
Aro Biotherapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0